Cancer will affect 2 in every 5 Canadians in their lifetime, with just over 25% representing new breast cancer diagnoses in women. Despite significant progress in the treatment of the most common cancer in women, resistance to chemotherapeutic agents remains a consistent obstacle in terms of the successful treatment of many types of breast cancers. The Mitacs-funded collaboration between NuvoBio and the Biggar lab at Carleton University is seeking to address this issue by systematically designing and developing peptide-based inhibitors that hold the promise as new therapeutics.

This collaboration between pharmaceutical company NuvoBio and a Research Team led from the University of Windsor and working with Dalhousie and the University of Western Ontario seeks to develop a new vaccine for lung cancer. The students and postdoctoral fellows will be making new types of molecules and investigating some underlying questions about how we formulate vaccines, as well as preparing these promising compounds and studying their safety an efficiency in preventing and eliminating lung cancers.